Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05983770 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Tegoprubart in Patients Undergoing Kidney Transplantation
A Phase 2 study, sponsored by Eledon Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 127
- Enrollment target
NCT05983770 is a Phase 2 study that has completed, run by Eledon Pharmaceuticals. The registered enrollment target is 127 participants.
The verdict
NCT05983770, a Phase 2 study, has completed, sponsored by Eledon Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 127 participants
- Enrollment target
Study Summary
This study will evaluate the safety and efficacy of AT-1501 compared with tacrolimus in patients undergoing kidney transplantation.
Interventions
- DRUG Tacrolimus
- DRUG AT-1501
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 127 participants |
| Start Date | 2023-08-30 |
| Est. Completion | 2025-09-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05983770
The ClinicalTrials.gov registry entry for NCT05983770 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 127 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eledon Pharmaceuticals, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Tacrolimus is the first listed.
NCT05983770 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05983770 about?
NCT05983770 is a clinical study titled "Safety and Efficacy of Tegoprubart in Patients Undergoing Kidney Transplantation". This study will evaluate the safety and efficacy of AT-1501 compared with tacrolimus in patients undergoing kidney transplantation.
What is the current status of trial NCT05983770?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 127 participants. The study started on 2023-08-30. Estimated completion is 2025-09-25.
What interventions are being tested in trial NCT05983770?
The interventions under investigation include: Tacrolimus (DRUG), AT-1501 (DRUG).
Who is sponsoring clinical trial NCT05983770?
This trial is sponsored by Eledon Pharmaceuticals, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.